Get started
Author

Andreas Baumann

Observed names: A Baumann, A. Baumann, ANDREAS BAUMANN
Institution: Bayer (Germany)
ORCID: 0000-0003-3034-4288
Observed ORCID: 0000-0003-3034-4288
OpenAlex ID: A5074452979
PEGylated Biopharmaceuticals
2015 · Inge A. Ivens, William Achanzar, et al. · Toxicologic Pathology · 167
PDF
Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?
2014 · Andreas Baumann, Dietrich Tuerck, et al. · Drug Discovery Today · 164
Early Development of Therapeutic Biologics - Pharmacokinetics
2005 · A. Baumann · Current Drug Metabolism · 124
Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath ® ) in patients with chronic lymphocytic leukaemia and its link to treatment response
2007 · D. R. Mould, A. Baumann, et al. · British Journal of Clinical Pharmacology · 117
PEG ylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers
2012 · I. A. Ivens, A. Baumann, et al. · Haemophilia · 109
PDF
The Use of Tissue Slices for Pharmacotoxicology Studies
1996 · Peter H. Bach, Alison E.M. Vickers, et al. · Alternatives to Laboratory Animals · 82
Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys
2017 · Jian-Ming Gu, Xiao-Yan Zhao, et al. · The AAPS Journal · 45
PDF
Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial
2012 · Christopher Horvath, Laura Andrews, et al. · Nature reviews. Immunology · 38
Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction
2019 · Andreas Baumann, Isabel Piel, et al. · European Journal of Pharmaceutical Sciences · 34
PDF
Nonclinical development of biopharmaceuticals
2009 · Andreas Baumann · Drug Discovery Today · 34
New challenges and opportunities in nonclinical safety testing of biologics
2014 · Andreas Baumann, Kelly Flagella, et al. · Regulatory Toxicology and Pharmacology · 26
Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper
2022 · Karelle Ménochet, Hongbin Yu, et al. · mAbs · 25
Current challenges and opportunities in nonclinical safety testing of biologics
2013 · Sven Kronenberg, Andreas Baumann, et al. · Drug Discovery Today · 24
Identification of 3α-hydroxy-cyproterone acetate as a metabolite of cyproterone acetate in the bile of female rats and the potential of this and other already known or putative metabolites to form DNA adducts in vitro
1995 · Rasoul S. Kerdar, Andreas Baumann, et al. · Carcinogenesis · 24
Use of Rat and Human Liver Slices for the Detection of Steroid Hormone‐Induced DNA‐Adductsin vitroby Means of the32P‐Postlabeling Technique
1996 · Andreas Baumann, Rasoul S. Kerdar, et al. · Pharmacology & Toxicology · 23
Nonclinical safety testing of biopharmaceuticals – Addressing current challenges of these novel and emerging therapies
2015 · Frank R. Brennan, Andreas Baumann, et al. · Regulatory Toxicology and Pharmacology · 21
Non-clinical Safety Evaluation of Biotherapeutics – Challenges, Opportunities and new Insights
2016 · Guenter Blaich, Andreas Baumann, et al. · Regulatory Toxicology and Pharmacology · 19
Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: Serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum
1993 · W. Kuhnz, A. Baumann, et al. · Contraception · 18
PEGylated biologics in haemophilia treatment: Current understanding of their long‐term safety
2019 · Andreas Baumann · Haemophilia · 17
PDF
Challenges of non-clinical safety testing for biologics: A Report of the 9th BioSafe European Annual General Membership Meeting
2021 · Thomas Kissner, Guenter Blaich, et al. · mAbs · 12
Preclinical development of therapeutic biologics
2008 · Andreas Baumann · Expert Opinion on Drug Discovery · 12
DNA Adduct Formation of Selected Sex Steroids in Human Liver Slices In Vitro
1998 · W. Feser, R.S. Kerdar, et al. · Toxicology in Vitro · 12
Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women
1996 · A. Baumann, A. Fuhrmeister, et al. · Contraception · 11
In Vitro Model of the Human Liver Parenchyma to Study Hepatotoxic Side Effects of Dy-EOB-DTPA
2000 · DAGMAR HÖGEMANN, ANDREAS BAUMANN, et al. · Investigative Radiology · 10
Biotherapeutics in non-clinical development: Strengthening the interface between safety, pharmacokinetics-pharmacodynamics and manufacturing
2018 · Peter Ulrich, Guenter Blaich, et al. · Regulatory Toxicology and Pharmacology · 9
Works count: 39
Citation count: 1,217
H-index: 18
I10-index: 24
Year
Topic
Type